Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Hepatocellular 29Carcinoma, Renal Cell 17Liver Neoplasms 12Breast Neoplasms 10Carcinoma, Non-Small-Cell Lung 9Neoplasms 5Leukemia, Myeloid, Acute 5Kidney Neoplasms 5Neoplasm Metastasis 4Urinary Bladder Neoplasms 3Thyroid Neoplasms 3Prostatic Neoplasms 3Lung Neoplasms 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Lymphocytic, Chronic, B-Cell 3Colorectal Neoplasms 3Carcinoma 3Thyroid Carcinoma, Anaplastic 2Thyroid Cancer, Papillary 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Myelodysplastic Syndromes 2Multiple Myeloma 2Breast Neoplasms, Male 2Blast Crisis 2Adenocarcinoma, Follicular 2Urethral Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Thyroid cancer, medullary 1

Interventions

Carboplatin 11Pemetrexed 8Paclitaxel 8Radiotherapy 7Docetaxel 7Bevacizumab 7Cisplatin 6Gemcitabine 5pembrolizumab 3Taxes 3Metformin 3Vinorelbine 2Thalidomide 2Radiotherapy, Conformal 2Nivolumab 2Cetuximab 2trametinib 1sintilimab 1satraplatin 1ribociclib 1pegfilgrastim 1naporafenib 1motexafin gadolinium 1milademetan 1cixutumumab 1atezolizumab 1anetumab ravtansine 1aldesleukin 1Watchful Waiting 1Surgical Procedures, Operative 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Adenocarcinoma of Lung × Sorafenib × Clear all
NCT00754923 2019-03-06

Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Ohio State University Comprehensive Cancer Center

Phase 2 Terminated
11 enrolled 8 charts
Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡